Despite losing a potentially lucrative FLT3 inhibitor partnership with Astellas Pharma Inc...for $1.3 billion in 2004, began its second life when the big pharma spun out the firm and lead asset ETC-1002 in 2008. (See BioWorld Today, May 2, 2008.) It raised $22.8 million in a Series A round and recently added $33 million in a preferred stock deal...Proceeds would be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for

Gross proceeds totaled about $35 million, with net proceeds of $32.8 million to fund SFP clinical trials and for other general corporate purposes

The firm also has programs in two big pharma partnerships...Sirona Biochem Corp., of Vancouver, British Columbia, said it closed equity and debt financings for gross proceeds of C$975,000 (US$967,644), bringing the total capital raised to date in 2013 to C$2.4 million

MEI Pharma Inc., of San Diego, priced a public offering of about 2 million shares of common stock at $7.50 apiece, a 9.5 percent discount to Thursday's closing price...Gross proceeds are expected to total about $15.2 million

A full overallotment option would bring gross proceeds from the IPO to $64.4 million, putting it close to the $69 million the firm had hoped to raise when it first filed an S-1 late last year. (See BioWorld Today, Nov. 8, 2012.) The positive reception to the newly listed shares wasn't surprising, given Enanta's work in the hot HCV space, along with its lucrative partnerships with Novartis AG and Abbott (now AbbVie...and London-based GW Pharma plc, which is seeking a Nasdaq listing and a capital

The company plans to use proceeds from the offering to complete clinical development of Ravicti in hepatic encephalopathy (HE) and to fund post-approval studies in UCD...Hyperion gained rights to Ravicti from Ucyclyd Pharma Inc., a subsidiary of Scottsdale, Ariz.-based Medicis Pharmaceutical Corp...at the same unit price.

As this money is dispensed through its clinical development programs, the company expects to receive £12 million in government R&D tax credits, bringing the total pot to £60 million...Pharma doesn't want more questions than answers, so you can't do development on a shoestring or cut corners...The total amount raised in the private placement is $7.9 million.

to the tune of about $50 million in gross proceeds, coming the firm's way through a public offering expected to close later this month...Clinical Cancer Research included a paper that suggested the compound, ENMD-2076, acts potently against breast cancer cell lines that lack expression of the estrogen and progesterone receptors, while also lacking HER2 amplification, i.e., TNBC

Gross proceeds from the private placement were $27.5 million, before deducting fees and expenses...NeRRe Therapeutics Ltd., of London, raised £11.5 million (US$18.4 million) to develop a portfolio of clinical and preclinical neurokinin receptor antagonists divested from GlaxoSmithKline plc, also of London.

Data also indicated rapid onset of activity, with clinical activity reported for 16 of 19 responders occurring within the first two cycles of treatment...OncoSec plans to use the proceeds to fund clinical trials and research and development and for other corporate purposes...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.

also participated in the financing, an unusual syndicate formed by investment funds of multiple large pharma companies...Supernus Pharmaceuticals Inc., of Rockville, Md., is raising $48 million in gross proceeds through a public offering

At least a year shy of the next milestone payment from partner Astellas Pharma Inc., Ambit Biosciences Inc...With the overallotment, the company sold a total of 22.8 million shares for gross proceeds of $23 million...The net proceeds will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's recently initiated Phase IIb trial of personalized T-cell therapy Tcelna in patients with secondary progressive multiple sclerosis

Shares of MEI Pharma Inc. (NASDAQ:MEIP) popped on Monday morning and climbed throughout the day after the company disclosed a $27.5 million private placement...The company laid groundwork for clinical trials in advance of the financing and plans to begin a "very substantial" randomized Phase II study in the U.S...Novelos plans to use the proceeds to complete an in-house clinical-stage manufacturing facility for its small-molecule, broad-spectrum, cancer-targeted imaging agent I-124-CLR1404 (LIGHT

Isotechnika Pharma Inc., of Edmonton, Alberta, completed the second tranche of its nonbrokered private placement, raising additional gross proceeds of $151,000 by the issuance of about 3.7 million units at a price of 4 cents per unit

About a year earlier, Dutch firm AM-Pharma BV banked €29.2 million (then US$39.8 million) in a Series D round, apparently the largest venture capital financing in Dutch biotechnology thus far...The company planned to switch from a bovine to a recombinant form of its AKI treatment, alkaline phosphatase. (See BioWorld Today, Sept. 14, 2011.) Bunnik, the Netherlands-based AM-Pharma had then gained only preliminary data from two small-scale clinical trials suggesting that bovine alkaline phosphatase

Noting a trend for pharma companies to engage in more collaborations and acquisitions in order to supplement their pipelines with new technology, Lammers said he could envision such an outcome for Mirna...Given the interest of big pharma in microRNA companies, including Mirna, I'm convinced if we have strong human proof-of-concept data in the clinic, most likely pharma will be interested in stepping up to the plate," Lammers said

The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.

The gross proceeds to Horizon are expected to be about $75 million...Royalty Pharma has invested $25 million under its royalty arrangement with Sunesis, and, in a separate transaction, a syndicate of lenders funded the second tranche of $15 million under their $25 million loan facility with the company

Tranzyme Pharma Inc., of Research Triangle Park, N.C., said it closed a registered direct offering of approximately 3 million shares of its common stock at $3.85 per share for gross proceeds, including an overallotment option, of $11.5 million